The Ultimate Peptide Stack? Gain Muscle, Lose Fat!

JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT] Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2 HEALTH AUTONOMY [COURSE] Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy JOIN THE COMMUNITY Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2 EMAIL LIST 1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6 HIRE ME FOR CONSULTING: Consulting: https://bit.ly/3dmUl2H Created with Biorender 0:00 - Introduction 0:32 - Lose Fat, Gain Muscle? 5:00 - Replace the ‘A’ with a ‘B’ 7:34 - More Direct Evidence 8:40 - Side Effects 9:08 - Something more Effective... Extremely impressive Peptide:    • This Peptide will Revolutionize Health!   References* *Full Funding/Conflicts are provided in the free article (found in email list and Physionic Community Article Library) [1] Pirruccello-Straub M, Jackson J, Wawersik S, et al. Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Scientific Reports. 2018;8(1):2292. doi:10.1038/s41598-018-20524-9. [Study 905] Pratley RE, Denham DS, Trivedi R, Watkins E, Connery L, Barnes J, et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine. Published online June 8, 2026. doi:10.1038/s41591-026-04440-4. [Study 906] Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nature Medicine. 2026;32(3):869–882. doi:10.1038/s41591-026-04204-0. [Study 907] Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Network Open. 2021;4(1):e2033457. doi:10.1001/jamanetworkopen.2020.33457. [Study 908] Crawford TO, Servais L, Mercuri E, Kölbel H, Kuntz N, Finkel RS, et al.; SAPPHIRE Study Group. Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy: a phase 3, double-blind, randomised, placebo-controlled trial. The Lancet Neurology. 2025;24(9):727–739. doi:10.1016/S1474-4422(25)00225-X. [Study 909] Mastaitis JW, Gomez D, Raya JG, Li D, Min S, Stec M, et al. GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates. Nature Communications. 2025;16(1):4377. doi:10.1038/s41467-025-59485-9. [Study 910] Gonzalez Trotter D, Donahue S, Wynne C, Ali S, Parasoglou P, Boyapati A, et al. GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial. Nature Communications. 2025;16(1):4376. doi:10.1038/s41467-025-59380-3. Please use the following link to submit your critique: https://bit.ly/PhysionicCritique Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.